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ABSTRACT
Background and Objectives: The relationship between ejection fraction (EF), N-terminal 
pro-brain natriuretic peptide (NT-proBNP) levels and renal function is unknown as stratified 
by heart failure (HF) type. We investigated their relation and the prognostic value of renal 
function in heart failure with preserved ejection fraction (HFpEF) vs. reduced ejection 
fraction (HFrEF).
Materials and Methods: NT-proBNP, glomerular filtration rate (GFR), and EF were obtained 
in 1,932 acute heart failure (AHF) patients. HFrEF was defined as EF<50%, and renal 
dysfunction as GFR<60 mL/min/1.73 m2 (mild renal dysfunction: 30≤GFR<60 mL/min/1.73 
m2; severe renal dysfunction: GFR<30 mL/min/1.73 m2). The primary outcome was 12-month 
all-cause death.
Results: There was an inverse correlation between GFR and log NT-proBNP level (r=−0.298, 
p<0.001), and between EF and log NT-proBNP (r=−0.238, p<0.001), but no correlation 
between EF and GFR (r=0.017, p=0.458). Interestingly, the prevalence of renal dysfunction 
did not differ between HFpEF and HFrEF (49% vs. 52%, p=0.210). Patients with renal 
Korean Circ J. 2017 Sep;47(5):727-741
https://doi.org/10.4070/kcj.2017.0050
pISSN 1738-5520·eISSN 1738-5555
Original Article
Received: Mar 9, 2017
Revised: May 2, 2017
Accepted: Jun 6, 2017
Correspondence to
Dong-Ju Choi, MD, PhD
Cardiovascular Center, Seoul National 
University Bundang Hospital, Seoul National 
University College of Medicine, 82, Gumi-ro 
173-beon-gil, Bundang-gu, Seongnam 13620, 
Korea.
Tel: +82-31-787-7007
Fax: +82-31-787-7041
E-mail: djchoi@snubh.org
*Chan Soon Park and Jin Joo Park contributed 
equally to this work.
Copyright © 2017. The Korean Society of 
Cardiology
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted noncommercial 
use, distribution, and reproduction in any 
medium, provided the original work is properly 
cited.
ORCID iDs
Chan Soon Park 
https://orcid.org/0000-0003-1717-6662
Jin Joo Park 
https://orcid.org/0000-0001-9611-1490
Il-Young Oh 
https://orcid.org/0000-0002-5584-605X
Chang-Hwan Yoon 
https://orcid.org/0000-0001-6305-4442
Dong-Ju Choi 
https://orcid.org/0000-0003-0146-2189
Chan Soon Park , MD1,10,*, Jin Joo Park , MD1,*, Il-Young Oh , MD1,  
Chang-Hwan Yoon , MD1, Dong-Ju Choi , MD, PhD1, Hyun-Ah Park , MD2,  
Seok-Min Kang , MD3, Byung-Su Yoo , MD4, Eun-Seok Jeon , MD5,  
Jae-Joong Kim , MD6, Myeong-Chan Cho , MD7, Shung Chull Chae , MD8,  
Kyu-Hyung Ryu , MD9, Byung-Hee Oh , MD10, and on behalf of the KorHF 
Investigators
1 Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University 
Bundang Hospital, Seongnam, Korea
2Department of Family Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea
3Division of Cardiology, Yonsei University Severance Hospital, Seoul, Korea
4Division of Cardiology, Yonsei University Wonju Severance Christian Hospital, Wonju, Korea
5 Department of Internal Medicine, Sungkyunkwan University College of Medicine, Samsung Medical Center, 
Seoul, Korea
6Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
7Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
8Department of Internal Medicine, Kyungpook National University College of Medicine, Daegu, Korea
9Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea
10 Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University 
Hospital, Seoul, Korea
Relation of Renal Function with Left 
Ventricular Systolic Function and 
NT-proBNP Level and Its Prognostic 
Implication in Heart Failure with 
Preserved versus Reduced Ejection 
Fraction: an analysis from the Korean 
Heart Failure (KorHF) Registry
Hyun-Ah Park 
https://orcid.org/0000-0003-2343-8964
Seok-Min Kang 
https://orcid.org/0000-0001-9856-9227
Byung-Su Yoo 
https://orcid.org/0000-0002-3395-4279
Eun-Seok Jeon 
https://orcid.org/0000-0002-9946-5611
Jae-Joong Kim 
https://orcid.org/0000-0002-2714-2282
Myeong-Chan Cho 
https://orcid.org/0000-0002-0047-0227
Shung Chull Chae 
https://orcid.org/0000-0002-9871-6976
Kyu-Hyung Ryu 
https://orcid.org/0000-0001-9329-2716
Byung-Hee Oh 
https://orcid.org/0000-0002-9945-4306
Conflict of Interest
The authors have no financial conflicts of 
interest.
dysfunction had higher 12-month mortality in both HFpEF (7.9% vs. 15.2%, log-rank 
p=0.008) and HFrEF (8.6% vs. 16.8%, log-rank p<0.001). Multivariate analysis showed 
severe renal dysfunction was an independent predictor of 12-month mortality (hazard ratio 
[HR], 2.08; 95% confidence interval [CI], 1.40–3.11). When stratified according to EF: the 
prognostic value of severe renal dysfunction was attenuated in HFpEF patients (HR, 1.46; 
95% CI, 0.66–3.21) contrary to HFrEF patients (HR, 2.43; 95% CI, 1.52–3.89).
Conclusion: In AHF patients, the prevalence of renal dysfunction did not differ between 
HFpEF and HFrEF patients. However, the prognostic value of renal dysfunction was 
attenuated in HFpEF patients.
Keywords: Renal dysfunction; Ejection fraction; Pro-brain natriuretic peptide (1-76); 
Prognosis; Heart failure
INTRODUCTION
Heart failure (HF) is the leading cause of death and hospital admission in the United States 
and worldwide including Korea. Its incidence and prevalence are increasing, and it has a 
substantial mortality and morbidity rate.1-3)
There exist bidirectional interactions between heart and kidney, and clinical conditions 
in which either the diseased kidney or heart makes the other organ dysfunctional; this is 
defined as cardio-renal syndrome (CRS). The proposed mechanisms include neurohormonal 
(i.e., autonomous nerve system, renin-angiotensin-aldosterone system, and natriuretic 
peptide system), and hemodynamic factors (i.e., arterial pressure and venous congestion).4)
N-terminal pro-brain natriuretic peptide (NT-proBNP) is a biomarker used to evaluate the 
degree of neurohormonal activation.5)6) Patients with HF with reduced ejection fraction 
(HFrEF) have higher NT-proBNP levels than those with preserved ejection fraction (HFpEF) 
suggesting they have different degrees of neurohormonal activation.7)8) Considering that 
NT-proBNP reflects the level of neurohormonal activation and patients with HFrEF had 
higher levels of NT-proBNP, the prevalence and prognostic value of renal dysfunction may be 
dependent on the type of HF.
In this study, we first investigated the relationship of renal function with left ventricular (LV) 
systolic function, and NT-proBNP level. Second, we examined the prevalence and prognostic 
value of renal dysfunction in HFpEF vs. HFrEF.
MATERIALS AND METHODS
Patients and data collection
The Korean Heart Failure (KorHF) Registry is a prospective multicenter registry designed 
to reflect the real-world clinical data of Korean patients admitted for acute heart failure 
(AHF). The study design and the primary results of the KorHF registry have been published 
elsewhere.9)
The registry was founded in June 2004 and is supported by the Korean Society of Heart 
Failure. Twenty-four well-qualified centers participated in the registry. All consecutive patients 
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hospitalized with an episode of AHF as the primary reason for admission were eligible for 
enrolment. HF was diagnosed at admission according to the Framingham criteria.10)
Patients with new-onset (de novo) AHF as well as those with acutely decompensated HF 
(ADHF) were included. ADHF was defined as worsening of HF in patients with a previous 
diagnosis or hospitalization for HF. New-onset AHF was defined as AHF in patients with 
no previous history of HF. A confirmed diagnosis of HF at discharge was also required. All 
patients were strongly recommended for follow-up assessments for at least 1 year, and follow-
up outcome data including mortality and re-hospitalization because of HF, were prospectively 
collected using medical records and by telephone contact. The mean observational period 
was 1.7 years (range, 0.1–4.9 years), from June 2004 to April 2009. The institutional review 
board or ethics committee at each participating hospital approved the study protocol and 
patients gave written informed consent before study entry. The investigation conformed to 
the principles outlined in the Declaration of Helsinki.
For laboratory tests, leukocytes, hemoglobin, blood urea nitrogen (BUN), creatinine (Cr), 
serum sodium, troponin I, and NT-proBNP levels measured at admission were collected for 
the registry. Blood sampling and tests were conducted as routine practice by laboratories at 
each center certified by The Korean Association of Quality Assurance for Clinical Laboratory. 
Patients underwent echocardiographs during hospitalization for AHF. Estimated glomerular 
filtration rate (eGFR) was calculated from Cr values using the modification of diet in renal 
disease (MDRD) formula.11) Preserved renal function and renal dysfunction were defined 
as GFR≥60 mL/min/1.73 m2 and GFR<60 mL/min/1.73 m2, respectively. Patients with renal 
dysfunction were further classified as mild (30≤GFR<60 mL/min/1.73 m2) and severe renal 
dysfunction (<30 mL/min/1.73 m2). HFpEF and HFrEF were defined as left ventricular ejection 
fraction (LVEF) ≥50% and LVEF<50%, respectively.12)13) Data were collected at each site by a 
trained study coordinator using a standardized case report form and entered into the KorHF 
Registry database via a web-based electronic data capture system that included an electronic 
case report form. Data collection and audition were performed by the KorHF Registry 
Steering Committee at the Korean Society of Heart Failure.
Endpoints
The primary endpoint was 12-month all-cause death stratified by renal dysfunction and LVEF.
Statistical analysis
Data were presented as numbers and frequencies for categorical variables, and as 
mean±standard deviation (SD) or median with interquartile ranges for continuous variables. 
For comparison between groups, the χ2 test (or Fisher's exact test when any expected cell count 
was <5 for a 2×2 table) was used for categorical variables and unpaired Student's t-tests were 
applied for continuous variables. We calculated the area under the curve (AUC) of LVEF and log 
NT-proBNP level by receiver-operating-characteristics analysis to predict renal dysfunction. 
Kaplan-Meier curves were plotted and compared with the log-rank test. A multivariate Cox 
proportional hazards regression model was used to identify the independent predictors of 
all-cause death. Variables either associated with mortality with p<0.050 or reported to be 
associated with mortality were included as confounding variables in the multivariate analysis: 
age, sex, previous history of myocardial infarction, congestive HF, peripheral artery disease, 
chronic lung disease, diastolic blood pressure, hemoglobin, serum sodium, GFR, and NT-
proBNP. Two-sided p values <0.050 were considered statistically significant. Statistical tests 
were performed using IBM SPSS Statistics version 22 (SPSS Inc., Chicago, IL, USA).
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RESULTS
Baseline characteristics of the study population
Three-thousand two-hundred consecutive hospitalized AHF patients were enrolled in the 
KorHF Registry. Mean age was 67.6 years old and 50% were male, 47% had hypertension and 
31% had diabetes mellitus (DM). The overall 1-year mortality rate was 15%. Among them, 
GFR, LVEF, and NT-proBNP levels were available for 1,932 patients (60%). Mean age was 68 
years and 49% were male. Of these, 47% had hypertension, and 30% had DM, and 78% were 
New York Heart Association (NYHA) functional class III or IV. The mean ejection fraction 
(EF) was 39% and that of GFR was 62 mL/min/1.73 m2.
Overall, 51% had renal dysfunction; among them 38% had mild and 14% had severe renal 
dysfunction. Patients with renal dysfunction had more unfavorable baseline characteristics 
(Supplementary Table 1). With regard to LV systolic function, 524 patients (27%) were 
diagnosed with HFpEF and they had more unfavorable baseline characteristics, such as 
older age and higher prevalence of hypertension (Supplementary Table 2). The baseline 
characteristics of the patients according to renal dysfunction and EF are shown in Table 1. 
Patients with renal dysfunction were older. In addition, they had higher prevalence of DM, 
hypertension, myocardial infarction, and stroke history in both HFpEF and HFrEF groups. 
Concerning the laboratory parameters, patients with renal dysfunction showed lower 
hemoglobin, serum sodium level, and higher NT-proBNP level regardless of HFpEF and HFrEF.
The relationship between log NT-proBNP, EF, and GFR
There was a significant inverse correlation between GFR and log NT-proBNP level in all 
(r=−0.298, p<0.001), HFpEF (r=−0.359, p<0.001), and HFrEF patients (r=−0.284, p<0.001). 
Consequently, patients with renal dysfunction had higher log NT-proBNP levels than their 
counterparts (3.47 [3.09–3.79] vs. 3.85 [3.48–4.24]; p<0.001). Furthermore, there was an 
inverse correlation between LVEF and log NT-proBNP levels (r=−0.238, p<0.001), so that 
HFrEF patients had higher log NT-proBNP levels than HFpEF patients (3.02 [3.44–3.78] vs. 
3.74 [3.37–4.07]; p<0.001]. GFR did not correlate with LVEF (r=0.017, p=0.458), and there was 
no difference in GFR between the HFpEF and HFrEF (62.8±34.1 vs. 61.3±40.5 mL/min/1.73 
m2; p=0.462). Consequently, there was no difference in the prevalence of renal dysfunction 
between the 2 groups, either (49% vs. 52%; p=0.210) (Supplementary Figure 1A-F). There 
was no significant difference in NT-proBNP level whether patients were diagnosed as de novo 
HF or ADHF (median, 4,377.0 vs. 4,941.0; p=0.168).
In receiver-operating-curves analysis, the AUC of log NT-proBNP level to predict renal 
dysfunction was 0.71 (95% confidence interval [CI], 0.69–0.73) in all patients, 0.71 (95% CI, 
0.66–0.75) in HFpEF and 0.71 (95% CI, 0.69–0.74) in HFrEF patients. In contrast, the AUC of 
EF was only 0.51 (95% CI, 0.48–0.53) in all patients, 0.52 (95% CI, 0.47–0.57) in HFpEF and 
0.54 (95% CI, 0.51–0.57) in HFrEF patients (Figure 1). The risk of renal dysfunction increased 
with NT-proBNP levels, but not with LVEF (Figure 2).
Independent predictors of renal dysfunction were old age (odds ratio [OR], 1.50; 95% CI, 
1.18–1.90), being female (OR, 1.40; 95% CI, 1.12–1.75), having DM (OR, 1.63; 95% CI, 1.28–
2.07), hypertension (OR, 1.99; 95% CI, 1.59–2.48), history of congestive HF (OR, 1.59; 95% 
CI, 1.25–2.03), myocardial infarction (OR, 1.75; 95% CI, 1.26–2.43), hemoglobin<11.5 mg/dL 
(OR, 1.91; 95% CI, 1.52–2.39), serum sodium<135 mmol/L (OR, 1.61; 95% CI, 1.22–2.14), and 
log NT-proBNP ≥3.65 pg/mL (OR, 2.70; 95% CI, 2.18–3.35).
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Clinical outcomes according to EF and renal dysfunction
At 12-month follow-up, 241 patients (12.5%) died and 372 patients (19.3%) were readmitted. 
Patients who died had more unfavorable baseline characteristics, such as older age, previous 
history of myocardial infarction, congestive HF, peripheral artery disease and chronic lung 
disease. They had lower levels of hemoglobin, but higher levels of BUN, serum Cr, and NT-
proBNP (Supplementary Table 3).
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Figure 1. Association between renal dysfunction according to log NT-proBNP and LVEF. In receiver-operating-curves analysis, the AUC of log NT-proBNP (A) and 
LVEF (B) to predict renal dysfunction are presented. 
AUC = area under the curve; CI = confidence interval; EF = ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure reduced 
ejection fraction; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-brain natriuretic peptide.
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Figure 2. Association of NT-proBNP and LVEF with renal dysfunction. 
Patients were divided in quartiles according to LVEF and NT-proBNP. Risk on the y-axis is HR±95% CIs using a 
logistic regression model. 
CI = confidence interval; HR = hazard ratio; LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal pro-
brain natriuretic peptide; OR = odds ratio.
Patients with renal dysfunction had higher 12-month mortality (8.4% vs. 16.4%; log-rank 
p<0.001). When stratifying according to HF type, patients with renal dysfunction had 
higher mortality in both HFpEF (7.9% vs. 15.2%; log-rank p=0.008) and HFrEF (8.6% vs. 
16.8%; log-rank p<0.001) groups (Figure 3). Survival analysis of 4 groups according to LVEF 
and renal dysfunction is presented in Supplementary Figure 2. Concerning readmission, 
patients with renal dysfunction had a higher readmission rate (16.5% vs. 21.9%; log-rank 
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Figure 3. Survival rates according to renal dysfunction. Kaplan-Meier curves of the 12-month survival rates according to renal dysfunction in all (A), HFpEF (B), 
and HFrEF (C) patients are presented. 
GFR = glomerular filtration rate; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction.
p<0.001), however, when stratifying according to EF, patients with renal dysfunction had 
higher readmission only in the HFrEF (16.6% vs. 23.3%; log-rank p<0.001), but not in the 
HFpEF group (16.1% vs.18.0%; log-rank p=0.479) (Figure 4). With regard to severity of renal 
dysfunction, patients with severe renal dysfunction had worse outcomes (Supplementary 
Figures 3 and 4).
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Figure 4. Readmission free survival rates according to renal dysfunction. Kaplan-Meier curves for 12-month readmission free survival rates according to renal 
dysfunction in all (A), HFpEF (B), and HFrEF (C) patients are presented. 
GFR = glomerular filtration rate; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction.
In a Cox proportional hazard regression analysis, renal dysfunction was a significant 
predictor of 12-month mortality (mild renal dysfunction and hazard ratio [HR], 1.33; 95% 
CI, 0.65–2.70; severe renal dysfunction and HR, 2.08; 95% CI, 1.40–3.11) amongst others 
(Table 2). When stratifying according to HF type, severe renal dysfunction was a significant 
risk factor in HFrEF patients (HR, 2.43; 95% CI, 1.52–3.89). But its prognostic value was 
diminished in HFpEF patients (HR, 1.46; 95% CI, 0.66–3.21 across 30 mL/min/1.73 m2).
DISCUSSION
The main findings of this multicenter HF registry analysis are as follows; GFR was dependent 
on log NT-proBNP level, but independent of EF; and the prevalence of renal dysfunction was 
similar in HFpEF and HFrEF groups. Renal dysfunction was an independent risk factor for 
poor outcomes in all AHF patients. However, its prognostic value was attenuated in HFpEF 
patients, suggesting a differential prognostic value according to HF type.
735https://e-kcj.org https://doi.org/10.4070/kcj.2017.0050
Renal Dysfunction in HFpEF vs. HFrEF
Table 2. Multivariate Cox regression analysis for all-cause mortality
Characteristics Univariate analysis Multivariate analysis
*
HR 95% CI p value HR 95% CI p value
1-month death - - - - - -
HF patients (n=1,932) - - - - - -
GFR<60 mL/min/1.73 m2 reference - - - - 0.492
30≤GFR<60 mL/min/1.73 m2 1.03 0.39–2.71 0.949 0.89 0.50–1.60 0.698
GFR<30 mL/min/1.73 m2 1.10 0.30–3.99 0.886 1.33 0.65–2.70 0.437
NT-proBNP≥4,508.5 pq/mL 2.42 1.52–3.86 <0.001 2.46 1.39–4.35 0.002
HFpEF patients (n=524) - - - - - -
GFR<60 mL/min/1.73 m2 - - 0.990 - - 0.769
30≤GFR<60 mL/min/1.73 m2 1.10 0.30–3.99 0.886 0.61 0.14–2.68 0.510
GFR<30 mL/min/1.73 m2 1.03 0.39–2.71 0.949 0.75 0.26–2.13 0.586
NT-proBNP≥4,508.5 pq/mL 1.74 0.72–4.20 0.218 1.79 0.67–4.75 0.244
HFrEF patients (n=1,408) - - - - - -
GFR<60 mL/min/1.73 m2 - - <0.001 - - 0.211
30≤GFR<60 mL/min/1.73 m2 3.57 1.91–6.70 <0.001 1.91 0.825–4.444 0.131
GFR<30 mL/min/1.73 m2 1.53 0.85–2.76 0.155 1.03 0.502–2.109 0.938
NT-proBNP≥4,508.5 pq/mL 2.83 1.56–5.11 0.001 3.77 1.672–8.500 0.001
12-month death - - - - - -
HF patients (n=1,932) - - - - - -
GFR<60 mL/min/1.73 m2 - - <0.001 - - 0.001
30≤GFR<60 mL/min/1.73 m2 1.60 1.19–2.15 0.002 1.13 0.81–1.58 0.479
GFR<30 mL/min/1.73 m2 3.49 2.52–4.85 <0.001 2.08 1.40–3.11 <0.001
NT-proBNP≥4,508.5 pq/mL 2.11 1.62–2.76 <0.001 - - -
HFpEF patients (n=524) - - - - - -
GFR<60 mL/min/1.73 m2 - - 0.008 - - 0.644
30≤GFR<60 mL/min/1.73 m2 1.67 0.93–2.99 0.088 1.18 0.62–2.23 0.611
GFR<30 mL/min/1.73 m2 2.83 1.46–5.49 0.002 1.46 0.66–3.21 0.349
NT-proBNP≥4,508.5 pq/mL 2.72 1.64–4.53 <0.001 2.07 1.16–3.71 0.014
HFrEF patients (n=1,408) - - - - - -
GFR<60 mL/min/1.73 m2 - - <0.001 - - <0.001
30≤GFR<60 mL/min/1.73 m2 1.58 1.12–2.23 0.010 1.10 0.74–1.63 0.653
GFR<30 mL/min/1.73 m2 3.76 2.57–5.49 <0.001 2.43 1.52–3.89 <0.001
NT-proBNP≥4,508.5 pq/mL 1.94 1.42–2.67 <0.001 1.51 1.03–2.20 0.033
CI = confidence interval; GFR = glomerular filtration rate; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with 
reduced ejection fraction; HR = hazard ratio; NT-proBNP = N-terminal pro-brain natriuretic peptide.
*HRs have been adjusted for age >65 years, sex, previous history of myocardial infarction, congestive HF, peripheral artery disease, chronic lung disease, 
diastolic blood pressure < median, hemoglobin < median, and serum sodium level <135 mmol/L.
It is of note that there was a significant inverse correlation between log NT-proBNP level, 
GFR, and LVEF; however, there was no significant correlation between GFR and LVEF, and the 
proportion of renal dysfunction was the same in HFpEF vs. HFrEF. The inverse relationship 
between log NT-proBNP levels and renal function has been previously reported.14)15) Although 
the renal dependence on clearance of NT-proBNP partly accounts for elevation of NT-proBNP 
level, the wide variation in NT-proBNP level among patients with renal dysfunction suggests 
that reduced renal clearance is only one of many mechanisms for NT-proBNP elevation.14) NT-
proBNP is a cardiac neurohormone that is mainly secreted from the ventricles in response to an 
increase in wall tension.16) According to the law of Laplace, wall tension correlates directly with 
wall pressure and LV diameter, but inversely with LV wall thickness. Thus, HFrEF patients with 
an enlarged LV cavity size have higher wall tension and higher NT-proBNP levels than HFpEF 
patients with an increased relative wall thickness and relatively preserved LV diameter.17)
Renal dysfunction in HF patients comprises 2 main components; i.e., intrinsic nephropathy 
and CRS. As for the intrinsic nephropathy, both HF and kidney disease share common 
comorbidities such as old age, hypertension, and DM. Nonetheless, these risk factors were 
more prevalent in HFpEF, so that we cautiously speculate that the proportion of intrinsic 
nephropathy may be higher in HFpEF than in HFrEF patients. Various comorbidities 
including DM are reported to cause endothelial inflammation in the microvasculature, 
leading to functional and structural abnormalities contributing to HFpEF development.18)19) 
Those comorbidities can also cause renal impairment by microvascular dysfunction, implying 
that HFpEF patients may at higher risk for renal impairment.20)21)
Concerning CRS, impaired hemodynamic status and excessive neurohormonal activation 
are the most often discussed mechanisms. In HF patients, inadequate renal perfusion due 
to low cardiac output, renal venous congestion, and excessive vasoconstriction can cause 
impaired renal function. Tang and Mullens22) showed in AHF patients with low LVEF, venous 
congestion was the strongest hemodynamic determinant for the development of worsening 
renal function, while impaired cardiac index had a limited contribution.12) This explains the 
lack of correlation between GFR and LVEF, because LVEF does not necessarily translate into 
cardiac index. NT-proBNP is a biomarker for neurohormonal activation and HFrEF patients 
had higher NT-proBNP levels. We also cautiously suggest that the proportion of CRS patients 
may be higher in HFrEF than in HFpEF.
Taken together, the different proportion of intrinsic nephropathy and CRS may explain 
the phenomenon of same prevalence of renal dysfunction in HFpEF and HFrEF despite the 
difference in NT-proBNP levels. In the candesartan in heart failure: assessment of reduction 
in mortality and morbidity (CHARM)-overall program, there was no correlation between GFR 
and LVEF, and patient proportion with renal dysfunction was 34.7% in the CHARM-preserved, 
33.0% in CHARM-added, and 42.6% in CHARM-alternative study, respectively.23) This may also 
explain the differential prognostic impact of impaired renal function on outcomes by LVEF.
Renal dysfunction is a well-known risk factor for worse clinical outcomes in HF patients.12-25) 
In this study we also showed that HF patients with renal dysfunction had higher 12-month 
mortality and readmission rates compared to those without renal dysfunction. However, 
when stratifying according to the EF, the prognostic value of renal dysfunction differed; in 
the HFrEF group, severe renal dysfunction was associated with an increased risk of 12-month 
mortality, while in the HFpEF group, its prognostic value was not statistically significant after 
adjustment for significant covariates.
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The impact of renal function on survival has been well studied in HFrEF patients, and 
patients with renal dysfunction showed poor prognosis.25-27) However, in patients with HFpEF, 
the data are limited. Rusinaru et al.28) showed that HFpEF patients with impaired function 
(defined as GFR<60 mL/min/1.73 m2) had a 1.43 fold increased risk for 7-year mortality, but 
no increase at 6 months. In the CHARM study, renal dysfunction had poor prognosis for 
both HFrEF and HFpEF patients.23) In a post-hoc propensity score analysis of the digoxin 
investigation group (DIG) trial, the chronic kidney disease (CKD)-associated mortality 
was worse in patients with diastolic HF than in those with systolic HF.29) The reason for the 
different prognostic impact between studies including ours may be explained by the different 
study populations, definitions of HFpEF, and study periods (Supplementary Table 4).
In our study, the 1-year survival did not differ between HFpEF and HFrEF patients (log-rank 
p=0.527, Supplementary Figure 5), which is in line with previous studies.12) Our results 
suggest that the contribution of renal dysfunction to worse outcomes seems to be attenuated 
in HFpEF. The HFpEF patients had more unfavorable baseline characteristics such as older 
age and hypertension among others; it is possible that the effect of renal dysfunction on 
outcomes may be diluted by other risk factors.
It is of note that NT-proBNP level remained a strong prognostic factor in both HFpEF and 
HFrEF patients.8) Thus, NT-proBNP seems to be a more robust prognostic marker for clinical 
outcomes than renal impairment, regardless of the type of HF.
Our study has several limitations. First, this is an analysis of a prospective cohort, albeit a 
large one, rather than a randomized trial, and therefore unmeasured confounding factors 
could have an influence on the relation between renal insufficiency, LV systolic function and 
clinical outcomes. Second, we only included patients who had available data on EF, NT-
proBNP level and GFR. Thus, we cannot exclude the possibility of selection bias. Third, we 
used the MDRD formula to calculate GFR which should be used for patients with stable renal 
function. The accuracy of the MDRD formula may not be warranted in AHF patients. Because 
we used LVEF during admission for AHF to classify HF, we do not know how many patients 
would be reclassified to chronic stable HF status, when considering the wide variation of 
LVEF between acute and chronic HF. Nonetheless, categorization during the acute phase has 
been widely accepted.9)17) Finally, pulmonary function tests were not routinely performed in 
these patients. Although there was no significant difference in previous history of chronic 
lung disease between HFpEF and HFrEF groups in this registry, this could introduce 
misdiagnosis of chronic obstructive lung disease to HFpEF.30)
In conclusion, in AHF patients, the prevalence of renal dysfunction did not differ between 
HFpEF and HFrEF patients. Renal dysfunction was independent of LV systolic function, but 
dependent on NT-proBNP level. Although severe renal dysfunction is a significant prognostic 
factor in HFrEF patients, its impact seems to be attenuated in HFpEF patients.
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